ArticleMedical journal, Armed Forces India2014
Intravenous immunoglobulin in pediatrics: A review.
Article in Medical journal, Armed Forces India, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Bickerstaff encephalitis: a comprehensive narrative review of pathophysiology, clinical features, and global health considerations.Annals of medicine and surgery (2012) · 2025Review
- Article
- Incidence of adverse events related to intravenous immunoglobulin therapy in children.Transfusion · 2025Article
- Bickerstaff encephalitis in childhood: a review of 74 cases in the literature from 1951 to today.Frontiers in neurology · 2024Review
- Immunoglobulin replacement therapies in inborn errors of immunity: a review.Frontiers in pediatrics · 2024Review
- Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review.Antibodies (Basel, Switzerland) · 2020Review
- The use of intravenous immunoglobulin therapy in a tertiary pediatric hospital.Saudi medical journal · 2020Article
- Safety evaluation of intravenous immunoglobulin in pediatric patients: a retrospective, 1-year observational study.Therapeutic advances in drug safety · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been a rapid expansion of the use of intravenous immunoglobulin (IVIG) for an ever-growing number of conditions. IVIG is used at a 'replacement dose' (400-600 mg/kg/month) in antibody deficiencies and is used at a high dose (2 g/kg) as an 'immunomodulatory' agent in an increasing number of immune and inflammatory disorders.(1) The limitations for IVIG are the cost of the preparation and the need for intravenous infusions. Due to the cost, shortages and growing use of IVIG there have been attempts to develop evidence-based guidelines for the use of IVIG in a wide variety of immune disorders in children and neonates. This commentary provides the recommendations and recent publication regarding the use of IVIG in various conditions in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.